GLP-1 receptor agonists for alcohol use disorder in real-world care
Official title: Real-world utilization, effectiveness, and safety of GLP-1 receptor agonists for alcohol use disorder
Funded at Emory University · NIH-11413626 · Data updated 2026-11-12
This project looks at how GLP-1 receptor agonists used for diabetes and heart health perform in real-world adults with alcohol use disorder.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project start | September 10, 2025 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $715,056 |
| NIH project number | 5R01AA032254-02 |
| Project ID | NIH-11413626 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with alcohol use disorder who are using or could use GLP-1 receptor agonists in real-world clinical settings.
✕Less likely to help
Patients not using GLP-1 receptor agonists or with contraindications may not see benefit from this research.
What this research studies
Using real-world data from optum health records and claims, the study will examine how GLP-1 receptor agonists are used for adults with alcohol use disorder and what outcomes occur, including safety signals and effectiveness. The research will apply causal inference methods and machine learning to identify subgroups that may benefit most, aiming to inform clinicians about when these medicines might be the best option for AUD patients. Data from electronic health records, lab results, and insurance claims across the US will be analyzed to generate evidence that complements ongoing clinical trials. The goal is to help physicians tailor treatments for AUD in diverse real-world patient populations.
Why it matters
Potential benefit: If successful, the findings could guide clinicians in choosing GLP-1 receptor agonists for AUD patients and improve personalized treatment decisions.
How similar studies have gone: Previous observational signals suggest potential benefits, but results need confirmation in diverse real-world populations.
Where this research is happening
-
Emory University
Atlanta, United States Active
Researchers
- Principal investigator: Wallach, Joshua David — Emory University
- Study coordinator: Wallach, Joshua David
Related research
Other NIH-funded projects on the same topics.
-
Functional Connectivity-Guided TMS for Alcohol Use Disorder
A new approach uses targeted brain stimulation to help people with alcohol use disorder stay abstinent longer by focusing treatment on specific brain circuits.
-
Alcohol Use Disorder and Suicidal Behavior: Finding Why They Occur Together
A study using Swedish population data to understand why alcohol use disorder relates to suicidal thoughts and acts, with the goal of improving risk prediction and prevention.
-
Non-hallucinogenic psilocybin derivative for alcohol use disorder
A new, safer psilocybin-like compound is being studied to help people with alcohol use disorder.
-
Identifying brain proteins linked to PTSD and alcohol use disorder
Researchers are studying brain proteins that may contribute to PTSD and alcohol use disorder in US veterans to find new ways to help people who struggle with both conditions.
-
Mu and Kappa Opioid Balance in Alcohol Use Disorder
A study using brain imaging to understand how the brain’s opioid system changes during early sobriety in adults with alcohol use disorder.
-
Telehealth support to prevent suicide in people with alcohol use disorder in Tanzania
A telehealth counseling program is being adapted to help reduce suicide risk for people with alcohol use disorder in emergency departments in Tanzania.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.